D.A. Davidson & CO. Purchases 2,181 Shares of Royalty Pharma plc (NASDAQ:RPRX)

D.A. Davidson & CO. lifted its holdings in shares of Royalty Pharma plc (NASDAQ:RPRX) by 4.7% in the fourth quarter, according to its most recent filing with the SEC. The firm owned 48,146 shares of the biopharmaceutical company’s stock after acquiring an additional 2,181 shares during the period. D.A. Davidson & CO.’s holdings in Royalty Pharma were worth $1,228,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Swedbank AB lifted its holdings in shares of Royalty Pharma by 2.0% during the third quarter. Swedbank AB now owns 11,027,370 shares of the biopharmaceutical company’s stock valued at $311,964,000 after acquiring an additional 213,900 shares during the period. Blue Trust Inc. lifted its position in shares of Royalty Pharma by 362.7% during the third quarter. Blue Trust Inc. now owns 1,203 shares of the biopharmaceutical company’s stock worth $32,000 after purchasing an additional 943 shares in the last quarter. Lake Street Advisors Group LLC acquired a new position in Royalty Pharma during the 3rd quarter worth $211,000. Forsta AP Fonden boosted its holdings in Royalty Pharma by 2.8% in the third quarter. Forsta AP Fonden now owns 242,400 shares of the biopharmaceutical company’s stock valued at $6,857,000 after acquiring an additional 6,500 shares during the last quarter. Finally, DekaBank Deutsche Girozentrale grew its position in shares of Royalty Pharma by 2.4% during the 3rd quarter. DekaBank Deutsche Girozentrale now owns 746,287 shares of the biopharmaceutical company’s stock worth $20,836,000 after buying an additional 17,159 shares during the period. Institutional investors own 54.35% of the company’s stock.

Royalty Pharma Stock Up 0.3 %

Royalty Pharma stock opened at $33.42 on Monday. Royalty Pharma plc has a fifty-two week low of $24.05 and a fifty-two week high of $33.69. The company has a debt-to-equity ratio of 0.64, a current ratio of 1.44 and a quick ratio of 1.44. The firm has a market capitalization of $19.26 billion, a price-to-earnings ratio of 23.05, a PEG ratio of 2.31 and a beta of 0.49. The company’s 50 day simple moving average is $29.18 and its 200 day simple moving average is $27.94.

Royalty Pharma (NASDAQ:RPRX) last released its quarterly earnings data on Tuesday, February 11th. The biopharmaceutical company reported $1.15 earnings per share for the quarter, beating the consensus estimate of $0.99 by $0.16. Royalty Pharma had a return on equity of 24.40% and a net margin of 37.94%. As a group, sell-side analysts anticipate that Royalty Pharma plc will post 4.49 EPS for the current year.

Royalty Pharma Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Monday, March 10th. Stockholders of record on Friday, February 21st will be paid a dividend of $0.22 per share. This is a boost from Royalty Pharma’s previous quarterly dividend of $0.21. This represents a $0.88 annualized dividend and a dividend yield of 2.63%. The ex-dividend date is Friday, February 21st. Royalty Pharma’s dividend payout ratio (DPR) is currently 57.93%.

Wall Street Analysts Forecast Growth

A number of equities analysts have issued reports on RPRX shares. StockNews.com raised shares of Royalty Pharma from a “hold” rating to a “buy” rating in a research note on Tuesday, November 5th. TD Cowen upgraded Royalty Pharma to a “strong-buy” rating in a research report on Tuesday, December 24th. One analyst has rated the stock with a hold rating, five have given a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Buy” and an average target price of $41.60.

Royalty Pharma Profile

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.